Meet our Leaders
The diversity of our team in experience, expertise, and industry makes us uniquely qualified to handle big data problems in healthcare and beyond.
Founder, President, & CEO
Founder, President & CEO
Nassib G. Chamoun is the Founder of HDAI, serves as its President and Chief Executive Officer, and is the primary inventor of its broad-based health data analytics platform. Previously, Chamoun was Founder, President and CEO of Aspect Medical Systems, which he led from startup to a $100M global, publicly-traded company. Chamoun is the primary inventor of Aspect’s premier product, the Bispectral Index™ (BIS™) technology, the first clinically validated direct measure of the effects of anesthetics on the brain. BIS™ technology is available in a majority of hospitals in the US, Europe and Japan, has been used on approximately 100 million patients and has been the subject of more than 3,500 published articles and abstracts. BIS™ technology has been proven to reduce the risk of awareness with recall during surgery, facilitate faster wake-ups with less recovery time and reduce anesthetic use. In 2009, Chamoun guided the acquisition of Aspect Medical by Covidien (now Medtronic), a leading $12 billion global healthcare products company. From 2009 to 2010 he assisted the CEO of Covidien in the capacity of Vice President of Technology, Research and Clinical Development.
While at Aspect Medical, Chamoun invented the Risk Stratification Index (RSI), a broadly applicable and robust system for assessing hospital length of stay and mortality in surgical patients based solely on administrative data. Over the years, he has published several peer reviewed papers on RSI, including in collaboration with Cleveland Clinic and the Lown Institute. Chamoun presently serves as Chairman of the Board of the Lown Institute, is a member emeritus of the Northeastern University Corporation and served as Director and Vice President of the Anesthesia Patient Safety Foundation from 2004 to 2010.
Chamoun earned a bachelor’s degree in Electrical Engineering from Northeastern University and a master’s degree in Computer Engineering from Boston University. Subsequently, he was a fellow in cardiovascular physiology at the Lown Cardiovascular Laboratory at the Harvard School of Public Health and was pursuing his PhD in biomedical engineering, when he withdrew to found Aspect Medical.
EVP & COOSee Phil’s Bio
EVP & COO
Mr. Devlin has worked in the medical device industry for over 30 years with experience in general management, sales, marketing, corporate strategy, business development, clinical research, regulatory, research, product development, and operations.
He has successfully grown several start-up medical ventures, including Aspect Medical, a $100 million global public company that was acquired by Covidien in 2009. While at Covidien/Medtronic, Mr. Devlin was general manager of two business units, Anesthetic Effect Monitoring ‘BIS’ and Sustainable Technologies. Additionally, he was responsible for M&A for the Respiratory and Monitoring Solutions business unit. He has led numerous M&A transactions on buy/sell side totaling over $1B invested. Most recently, Mr. Devlin was Chief Business officer and SVP New Ventures for Triple Ring Technologies, Inc.
Mr. Devlin received his BS and MS degrees in electrical engineering from Northeastern University. He is the author of numerous publications and is an inventor of more than 15 US patents.
Scott Greenwald, Ph.D.
Chief Scientist/VP of ResearchSee Scott’s Bio
Scott Greenwald, Ph.D.
Chief Scientist/VP of Research
Scott Greenwald, Ph.D. is the Chief Scientist and VP of Research of Health Data Analytics Institute. Dr. Greenwald has over 25 years experience managing development of innovative medical technologies and conducting analytical research. Dr. Greenwald previously served as VP of Technology for Hemedex, Inc., Sr. Director of Advanced Research for Covidien, and VP of Research for Aspect Medical Systems, Inc., creators of the Risk Stratification Index (RSI) and the Bispectral Index (BIS). Dr. Greenwald has broad technical and clinical research expertise in data mining, algorithm development, statistics, and outcomes research. He has authored 10+ US Patents and 100+ peer-reviewed abstracts and manuscripts.
Greenwald earned a BSE in Biomedical and Electrical Engineering from Duke University and an SM in Electrical Engineering and Computer Science from MIT. Dr. Greenwald received his Ph.D. in Medical Engineering from the Harvard-MIT Division of Health Sciences and Technology (HST), which included medical training at Harvard Medical School and clinical training at the Mount Auburn Hospital and MGH. His doctoral research utilizing Expert System technologies was conducted within the Clinical Decision Making Group of MIT’s Artificial Intelligence Laboratory.
Paul J. Manberg, Ph.D.
VP of Clinical & Regulatory AffairsSee Paul’s Bio
Paul J. Manberg, Ph.D.
VP of Clinical & Regulatory Affairs
Dr. Manberg has four decades of experience leading the regulatory and clinical development programs for a wide range of medical device and pharmaceutical products. He has designed and executed numerous US and international multicenter clinical trials leading to successful product registrations and market adoption activities while holding executive positions at Ares-Serono, Aspect Medical Systems, Covidien, and CSA Medical. Since 2011, Dr. Manberg has maintained an active clinical and regulatory strategic consulting practice for early-stage medical industry clients.
He received his BS degree in Biology from SUNY-Binghamton and his Ph.D. in Pharmacology from the University of North Carolina School of Medicine.
VP of Corporate StrategySee David’s Bio
VP of Corporate Strategy
David has worked closely with progressive health systems and physician groups on major strategic and financial issues. He began his career at The Advisory Board Company, a healthcare research and technology firm, where he focused on revenue cycle operations and accountable care strategy. As one of the firm’s experts on payment reform, David advised health system CFOs during the transition to value-based payment, with a particular focus on the financial and operational implications of bundled payment and shared savings contracts. He later worked as a senior manager for research at athenahealth, an EHR vendor, developing best practices and strategic guidance for physician group leaders based on insights from the country’s most complete source of EHR and practice management data. David and his team were also responsible for identifying new business lines that leverage athenahealth’s unique data asset.
David has a degree in public policy and political science from Duke University.
VP of Product DevelopmentSee Mike’s Bio
VP of Product Development
Mike has three decades of experience in Healthcare IT in the Boston area. He’s worked across a broad spectrum of the healthcare industry including Home Health, Specialty Pharma, Insurers and Inpatient & Outpatient clinical workflows. He has built and lead many teams that have developed industry-leading and best in KLAS software products. Mike also has extensive experience integrating and interfacing with major EMRs, claims systems and third party software vendors. Prior to coming to HDAI, Mike served as CTO – Trellis Rx, CTO – xG Health Solutions, VP Product Development – Healthwyse, VP Product Development – PatientKeeper and Director Software Development – McKesson Health Solutions.
Mike has a Bachelors of Science degree in Computer Science with a minor in Mathematics from Westfield State University.
VP of Customer EngagementSee Carola’s Bio
VP of Customer Engagement
Ms. Endicott has worked in the health care industry for over 30 years with experience in hospital administration, health care supply chain technology development, operational excellence, and software and hardware product strategy.
At Tufts Medical Center, Ms. Endicott served as VP for Clinical Support Services, with responsibility for operational, financial, and quality outcomes for the Cancer, Cardiovascular and ancillary areas. In 2004 she joined the founding team of WaveMark, a supply management and workflow solution serving as VP Hospital Services, Operations, and Product. WaveMark was acquired by Cardinal Health in 2013 and Ms. Endicott was responsible for Operations and Services growth and renewals. Ms. Endicott’s most recent position was VP Product Strategy at Cardinal Health/WaveMark.
Ms. Endicott sits on several non-profit boards including the American Memorial Hospital in Reims and Boston Cares in Boston.
Ms. Endicott received her BA in political science from Middlebury College, Middlebury, VT, and Ed.M. in organizational development from Harvard Graduate School of Education.
VP of Finance and OperationsSee Tim’s Bio
VP of Finance and Operations
Tim started his career in the Assurance practice of PricewaterhouseCoopers. After his exit from public accounting he spent several years in corporate finance roles at Boston Scientific and Dell/EMC. Tim led the efforts to file the registration statements for Covidien as they spun out of Tyco International, and was instrumental in the initial buildout of the Finance organization. He then moved into Corporate Development and worked both at the business unit and corporate level scouting and executing transactions to transform and grow the business. After the acquisition of Covidien by Medtronic, he served as the CFO of a diagnostics startup and most recently was the Corporate Controller for Markforged.
Tim has a degree in Accounting from Bentley University.
VP of Research and Foundation Partnerships
Board of Directors and Advisors
We are backed by investors and advisors who share our vision and keep us on track with our mission to extract value from health data and revolutionize its use across industries and institutions for the good of society. Our board members come from finance, medical device, health IT, research and academia, and they are committed to helping us get it right.
John J. O’Connor
ChairmanSee John’s Bio
John J. O’Connor
John J. O’Connor serves as Chairman of the HDAI Board. Mr. O’Connor is the former vice chairman of services for PricewaterhouseCoopers LLP. Prior to his retirement in 2006, O’Connor was responsible for the firm’s business lines, with combined revenues of $7 billion and 28,000 employees in 90 offices. During his career at PricewaterhouseCoopers, O’Connor also served as the leader of the firm’s U.S. audit practice, and prior to this, was the managing partner of the firm’s Boston office. He was a partner for 24 of his 33 years at PricewaterhouseCoopers.
O’Connor serves on several corporate Boards, including Abt Associates, LeMaitre Vascular, Inc. and mTuitive, Inc., as well as on several non-profit Boards, including the Dana-Farber Cancer Institute and the Harvard Medical Collaborative.
O’Connor holds a B.A. from Suffolk University in Boston and an executive MBA from the Amos Tuck School at Dartmouth College. He also graduated from the Harvard Business School’s Leadership in Professional Service Firms program.
Edwin M. Kania, Jr.
Co-FounderSee Edwin’s Bio
Edwin M. Kania, Jr.
Edwin M. Kania, Jr. is a co-founder of HDAI and serves on its Board. Mr. Kania is the co-founder of Flagship Pioneering, a leading life sciences venture firm. He was the firm’s Chairman between 2001 and 2014, and continues as Managing Partner for the Flagship funds raised during that period. Kania has 35 years of experience in the venture capital industry. Prior to co-founding Flagship in 2000, he served as Managing Partner at OneLiberty Ventures and as a General Partner at its predecessor firm, Morgan, Holland Ventures.
Throughout his professional career, Kania has operated as an investor and active partner to entrepreneurs in company building. His direct investment experience covers over 100 companies. In addition, he has been intimately involved in the launch and development of nearly twenty companies as the founding, lead or co-lead investor, and on occasion has assumed operating roles in support of management. The total value of the companies in which Kania has participated as founding or lead investor exceeds $10 billion. Kania presently serves on the Board of several private companies and has been a Director for numerous publicly-traded and private companies. He has also been a long-time Director of MassBio, a not-for-profit organization representing the Massachusetts biopharmaceutical industry, and is a member of Harvard Partners’ Innovation Advisory Board.
Kania earned his undergraduate degree in physics from Dartmouth College and his MBA from Harvard Business School.
Kenneth A. Froot
Co-FounderSee Kenneth’s Bio
Kenneth A. Froot
Kenneth A Froot is a co-founder of HDAI and serves on its Board. He is the André R. Jakurski Professor of Business Administration, Emeritus, at Harvard University’s Graduate School of Business Administration. His prior appointments at Harvard include HBS Director of Research, the Industrial Bank of Japan Professorship in Finance, and the Thomas Henry Carroll-Ford Foundation Visitor’s Chair. Prior to coming to Harvard, he held the Ford International Development Chair at MIT, where he joined the faculty in 1986. He has taught numerous courses in economics and finance, including more recently Capital Markets, International Finance, and Risk Management.
Professor Froot is also a founding partner of FDO Partners, LLC, State Street Associates and MKT MediaStats, firms producing investment and knowledge resources for global investors.
Professor Froot received his B.A. from Stanford University and his Ph.D. from the University of California at Berkeley. He spent the 1988-1989 academic year as an Olin Fellow at the National Bureau of Economic Research, where he served as Chair of the NBER’s Insurance Group. His research on a wide range of topics in finance, risk management, and international markets has been published in many journals and books.
DirectorSee Marcus’s Bio
Marcus Traill began his career as an analyst at Bank of New Zealand and Owens Group prior to joining the QuantRes group of companies. At QuantRes, a proprietary quantitative trading firm and global private investor, he has played key roles in the trading of various quantitative strategies and has been responsible for managing the operations of the group and overseeing the private investment strategy. He serves as a Director of QuantRes Asset Management Ltd and as an Investor Director at Starling Bank, a UK regulated mobile only bank.